A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

NCT03565900 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

277

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections

Interventions

BIOLOGICAL: V114
BIOLOGICAL: Prevnar 13™
BIOLOGICAL: PNEUMOVAX™23

Sponsor

Merck Sharp & Dohme LLC